IntroductionAntibiotic resistance decreases success of Helicobacter pylori (Hp) eradication. Recently published results show low rate of resistance and better compliance with moxifloxacin based regiments.Aims&methodsWhether 7 days moxifloxacin with lansoprasole and amoxycillin can be compared with 10 days moxifloxacin with lansoprasole and amoxycillin according to moxifloxacin resistance. Patients with non-ulcer dyspepsia who had culture and histology positive Hp infection (n = 150) were randomly assigned into two groups. The first group (n = 75) received moxifloxacin 400 mg/d during 7 days and the other (n = 75) received moxifloxacin 400 mg/d during 10 days. All patients received amoxycillin 1 g twice daily, lansoprasole 30 mg twice daily. All Hp cultures were tested for sensitivity to moxifloxacin.Results138 patients (92%) completed the study, 68 in the first group and 70 in the second. Eradication rates were 84% (57/68) and 76% (57/75) in the 7 days moxifloxacin group and 90% and 84% in the second group (63/70, 63/75) according to the PP and ITT analysis; p = n.s. Among 129 patients (86% of study group), 6% of strains were primary resistant to moxifloxacin.Eradication of moxifloxacin sensitive/resistant strains was 98%/66%, p < 0.05ConclusionAccording to our results we recommend 7 days moxiflixacin based triple therapy.

Aim: To show if there is any connection between the activity of inflammatory bowel disease (IBD), infection with Clostridium difficile (C. difficile) and thrombocytosis in our hospitalized patients. Methods: We performed a retrospective observational study to determine the incidence of C. difficile infection (CDI) and thrombocytosis in our patients with IBD hospitalized from January 1, 2007-December 31, 2012. Results: A total of 363 hospitalized patients were identified during the observed 6-year period with a diagnosed IBD (258 patients with ulcerative colitis (UC) and 105 patients with Crohn's disease (CD). 28 (21.7%) patients with the exacerbation of UC and 17 (34.7%) patients with the exacerbation of CD were positive for CDI. Thrombocytosis was present in 65 (50.4%) patients with the exacerbation of UC and 39 (79.6%) patients with the exacerbation of CD. 26 (14.6%) patients with IBD exacerbation (15 patients with UC and 11 patients with CD) had both CDI and thrombocytosis. Statistically significant difference was found only in the incidence of thrombocytosis in patients with UC compared to patients with CD and all IBD patients. Conclusion: We recommend testing all hospitalized IBD patients with an exacerbation for CDI because of the high prevalence of CDI in these patients and the prognostic implications of CDI in these patients. Further studies with a larger number of patients are needed to investigate the real importance of CDI and thrombocytosis in patients with IBD exacerbation and also to show if any connection between those two parameters exists.